Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Creative Biogene is committed to providing high quality products and services to help scientists around the world find solutions in biological research and drug discovery.
Adenoviruses have long been a popular viral vector for gene therapy because they are able to affect both replicating and non-replicating cells, accommodate large transgenes, and encode proteins without integrating into the host cell genome. More specifically, they are used as vectors to load recombinant DNA or protein therapeutics for targeted therapy by infecting targeted cells.
There are two main production platforms for gamma-retroviral and lentiviral vectors: transient processes, which involve transfection of plasmids (multiple or single) into appropriate cell lines, and stable processes, which involve the preparation of stable cell lines that produce viral vectors using packaging cell lines that express packaging and envelope genes.
Advances in genetic engineering methods have enabled the development of effective gene therapy approaches for a variety of diseases based on adeno-associated viruses (AAVs). AAVs can be effectively used to treat a wide range of inherited and acquired human diseases, more specifically monogenic inherited diseases, i.e. diseases caused by mutations in one gene.
As highly structured protein particles, VLPs are conducive to the uptake of antigen-presenting cells and can stimulate the host's innate and adaptive immune response functions. In the past three decades, VLPs have been widely used, especially in the field of vaccines. Some VLP-based vaccines have been used in commercial production or have entered different stages of clinical research.
As the core link of CAR-T cell therapy, lentiviral packaging technology plays a vital role in the field of tumor immunotherapy. In-depth research on the biological basis and production process of lentiviral packaging and overcoming the current challenges are of far-reaching significance for promoting the development of CAR-T cell therapy technology and even the progress of the entire field of tumor immunotherapy.
Copyright © 2026 Creative Biogene. All rights reserved.